US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?

 
• By Ramsey Baghdadi

Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.

Plans May Delay Coverage Or Impose Strict Prior Authorization Requirements • Source: Shutterstock

More from Market Access

More from Pink Sheet